Shares of Moderna (NASDAQ:MRNA) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday’s close ...

The outbreak of Hantavirus on a cruise ship has led to biotech and pharmaceutical stocks surging on reports of firms ...

Shares of Moderna ( MRNA) were up nearly 7% in recent trading, following a 12% jump Friday, after Bloomberg reported the ...

Moderna (MRNA) stock rose 4% on Monday, extending its 12% rally on Friday. What’s behind the move: The biotech is researching ...

A localized hantavirus outbreak aboard an Atlantic cruise ship triggered a brief, speculative frenzy in biotechnology stocks ...

However, Moderna's deep pipeline and innovative technology could eventually allow it to improve and deliver excellent returns ...

Moderna (MRNA) is back in focus after its Q1 2026 earnings, reporting revenue of US$389 million compared with US$108 million ...

Lyme disease is an illness caused by bacteria most commonly spread to humans from ticks. It can cause arthritis, muscle weakness and pain.

New phase 2 data from personalized cancer vaccine EVX-01 demonstrates a record-high rate of vaccine targets triggering a tumor-specific immune response The results reinforce that Evaxion’s pioneering ...

See more on Vaxcyte's (PCVX) and VAX-31’s broad pneumococcal vaccine pipeline, strong cash runway, and key 2026–2027 trial ...